Core Insights - Sapu BioScience announced a new peer-reviewed study published in the International Journal of Molecular Sciences, reinforcing the scientific basis for biomarker-guided taxane therapy and highlighting the company's leadership in the biology of Transforming Growth Factor Beta 2 (TGFB2) [1][2] Group 1: Research Findings - The study identifies good prognostic biomarkers dependent on TGFB2 and poor prognostic biomarkers independent of TGFB2 in breast cancer, indicating that TGFB2 is not only a prognostic marker but also a biological background factor determining patient benefit from standard chemotherapy like taxanes [1] - The findings provide direct guidance for Sapu's taxane project Sapu-001, which aims to enhance the efficacy and tolerability of taxane therapy through precise patient selection and optimized dosing [1] Group 2: Company Strategy - Sapu BioScience focuses on developing antisense therapeutic drugs targeting TGFB2, establishing one of the most comprehensive proprietary knowledge bases around this pathway in oncology, with a broad intellectual property portfolio covering various tumor types and treatment scenarios [2] - The CEO of Sapu BioScience emphasized that the biological characteristics defined by TGFB2 significantly impact chemotherapy response, presenting a clear opportunity to improve treatment outcomes through more precise patient selection [2] - Sapu-001, an injectable formulation of paclitaxel using Deciparticle technology, benefits from a team with extensive experience in taxane drug development, having previously contributed to the commercialization of Abraxane and Cynviloq™ [2]